This site is intended for healthcare professionals

AstraZeneca reaches settlement agreement resolving patent litigation related to Ultomiris.

Read time: 1 mins
Published:18th Mar 2022

Alexion, AstraZeneca’s Rare Disease group, has entered into a settlement agreement with Chugai Pharmaceutical Co., Ltd. (Chugai), resolving all patent disputes between the two companies related to Ultomiris (ravulizumab). In accordance with the settlement agreement, Alexion and Chugai have taken steps to withdraw patent infringement proceedings filed with US District Court for the District of Delaware and Tokyo District Court.

Under the terms of the agreement, Alexion will make a single payment of $775 million in the second quarter of 2022, for which a charge will be recognised through the non-core P&L in the first quarter of 2022. No further amounts are payable by either party. The settlement does not impact AstraZeneca’s financial guidance for 2022.

Condition: Paroxysmal Nocturnal Haemoglobinuria
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.